Meningococcal vaccines are used in the treatment of meningitis, septicemia, meningococcemia and pneumonia. Meningitis is characterized by inflammation of the membranes covering the brain and spinal cord. This type of inflammation is caused by infection of bacteria, viruses and by drugs.
Based on various cause of the disease, meningitis is classified into two main types: non-infectious meningitis and infectious meningitis. Non-infectious meningitis is a type of aseptic meningitis. Aseptic meningitis is caused by something other than the bacteria that typically cause acute meningitis. Non-infectious meningitis does not spread from person to person. Infectious meningitis is further sub-divided into bacterial meningitis, fungal meningitis, viral meningitis and parasitic meningitis. Bacterial meningitis is extremely severe form of the disease which is caused by bacteria such as Haemophilus influenzae, Neisseria meningitidis and Streptococcus pneumonia. These bacteria can spread from person to person through coughing and sneezing. Viral meningitis is mainly occurred by diarrhea causing virus. Fungal meningitis is rare in healthy people. However, person who has an impaired immune system is more prevalent with this form of the disease.
Septicemia arises from infections throughout the body. It includes infections in the lungs, urinary tract and abdomen. Meningococcemia is also caused by bacterium Neisseria meningitidis.
The global meningococcal vaccines market is segmented into conjugate vaccines, polysaccharide vaccines and combination vaccines. Conjugate vaccines reduce incidences of bacterial meningitis. This is due to prolonged immunization influence of the vaccine which is developed for various serogroups of bacteria. Major brands of conjugate vaccines include MenAfriVac, Nimenrix, Menactra, Meningitec, NeisVac-C and Menveo.
Polysaccharide provides immunity for a short period of time. Major brands of polysaccharide vaccines include NmVac4, Menomune, Bi Meningo, Mencevax and Quadri Meningo.
Combination vaccines are prepared with the combination of other microorganism. Major brands of combination vaccines include Menitorix and MenHibrix.
In terms of geographic, North America dominates the global meningococcal vaccines market. This is due to increased healthcare awareness in the region. The U.S. represents the largest market for meningococcal vaccines followed by Canada in North America. In Europe, France, Germany and the U.K. holds major share of meningococcal vaccines market. However, Asia is expected to show high growth rates in the next five years in global meningococcal vaccines market. This is due to increasing awareness among people about meningitis in the region. Several government associations have launched various immunization programs and awareness campaigns to provide education about meningococcal disease. Japan, China and India are expected to be the fastest growing meningococcal vaccines markets in Asia.
In recent time, increased government support is key driver for the global meningococcal vaccines market. Various government associations have launched mandate immunization programs for school children. This increases the demand of meningococcal vaccines to provide immunity against meningococcal disease.
However, stringent regulations hamper the growth of global meningococcal vaccines market. Increasing mergers and acquisitions between manufacturing companies and government bodies and rapid product launches are some of the major trends of global meningococcal vaccines market.
Some of the major companies operating in the global meningococcal vaccines market are GlaxoSmithKline plc, JN-International Medical Corporation, Novartis International AG, Sanofi SA, Pfizer, Inc. and Baxter International, Inc..
Key geographies evaluated in this report are:
Key features of this report